{"ticker": {"uuid": "191e68be-5cc0-440b-8bb6-a196b4a1efcb", "symbol": "XTLB", "name": "XTL Biopharmaceuticals Ltd ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBITDA forward of XTL Biopharmaceuticals Ltd. Sponsored ADR \u2013 LSX:A41X7J", "summary": "This article provides a financial overview, specifically the enterprise value to EBITDA forward, for XTL Biopharmaceuticals Ltd. Sponsored ADR (LSX:A41X7J) on the Lang & Schwarz Exchange. It appears to be a stub or a data point from a financial platform like TradingView, indicati", "url": "https://www.tradingview.com/symbols/LSX-A41X7J/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T05:09:50", "published_display": "12 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of XTL Biopharmaceuticals Ltd. \u2013 BOATS:XTLB", "summary": "This article identifies the enterprise value to revenue forward for XTL Biopharmaceuticals Ltd., traded under the ticker BOATS:XTLB. It appears to be a stub or a section from a financial data platform, providing a title without further details or analysis within the visible conte", "url": "https://www.tradingview.com/symbols/BOATS-XTLB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T23:10:58", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of XTL Biopharmaceuticals Ltd. \u2013 BOATS:XTLB", "summary": "This article provides the \"Price to earnings forward\" metric for XTL Biopharmaceuticals Ltd. (XTLB) listed on the Blue Ocean Alternative Trade System (BOATS) via TradingView. The page displays the current period value, change, and percentage change for this financial indicator, n", "url": "https://www.tradingview.com/symbols/BOATS-XTLB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T18:12:07", "published_display": "09 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of XTL Biopharmaceuticals Ltd. \u2013 TASE:XTLB", "summary": "This article displays the \"Enterprise value to EBIT forward\" for XTL Biopharmaceuticals Ltd. (TASE:XTLB) on TradingView. It provides financial data and indicates that the market was closed with no trades executed for the company. The page is a financial overview on TradingView fo", "url": "https://www.tradingview.com/symbols/TASE-XTLB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T11:39:25", "published_display": "08 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of XTL Biopharmaceuticals Ltd. \u2013 TASE:XTLB", "summary": "This article displays the \"Price to sales forward\" financial metric for XTL Biopharmaceuticals Ltd. (TASE:XTLB) directly from TradingView. It indicates that the company's market is currently closed with no trades recorded for this particular metric.", "url": "https://www.tradingview.com/symbols/TASE-XTLB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T04:10:09", "published_display": "08 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Completed The Acquisition Of Psyga Bio Ltd. >XTLB", "summary": "XTL Biopharmaceuticals Ltd. has completed the acquisition of Psyga Bio Ltd. This action, following the execution of a definitive transaction agreement on June 13, 2026, marks the finalization of the deal. As a result, Psyga Bio is now a wholly-owned subsidiary of XTL.", "url": "https://www.moomoo.com/news/post/72287199/xtl-completed-the-acquisition-of-psyga-bio-ltd-xtlb?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-01T20:41:45", "published_display": "01 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharma (NASDAQ: XTLB) closes Psyga Bio deal and $1.5M raise", "summary": "XTL Biopharma (NASDAQ: XTLB) has completed its acquisition of Psyga Bio Ltd., an Israeli biotechnology company focused on psychedelic and functional mushroom-derived therapeutics, making psychedelic operations its exclusive core business. XTL acquired approximately 83.40% of Psyg", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-0052a691327c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T08:09:45", "published_display": "01 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Completed the Acquisition of Psyga Bio Ltd.", "summary": "XTL Biopharmaceuticals (NASDAQ and TASE: XTLB) has completed the strategic acquisition of Psyga Bio Ltd., transforming XTL into a dedicated company in global psychedelic medicine. This acquisition expands XTL's intellectual property portfolio with clinical-stage biopharmaceutical", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/xtl-completed-the-acquisition-of-psyga-bio-ltd/2376301", "source_name": "The Manila Times", "published_at": "2026-07-01T01:10:56", "published_display": "01 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform", "summary": "XTL Biopharmaceuticals has completed the acquisition of Psyga Bio, gaining 83.40% ownership and establishing itself in the psychedelic medicine field. The acquisition provides XTL with an advanced clinical pipeline focused on Psilocybin for mental health disorders, a GMP manufact", "url": "https://www.quiverquant.com/news/XTL+Biopharmaceuticals+Completes+Acquisition+of+Psyga+Bio+to+Establish+Psychedelic+Biotechnology+Platform", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T21:20:00", "published_display": "30 Jun 2026 21:20", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL buys Psyga Bio, taking control of 83.4% of shares", "summary": "XTL Biopharmaceuticals (XTLB) has completed the acquisition of approximately 83.40% of Psyga Bio, transforming XTL into a psychedelic medicine company. This acquisition provides XTL with an advanced psilocybin-based clinical pipeline, a licensed GMP-ready manufacturing facility, ", "url": "https://www.stocktitan.net/news/XTLB/xtl-completed-the-acquisition-of-psyga-bio-17wlo192k8w4.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:09:45", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) holders pass all items at June 29 EGM", "summary": "XTL Biopharmaceuticals (XTLB) shareholders approved all proposals at their Extraordinary General Meeting (EGM) held on June 29, 2026, in Tel Aviv. The meeting was originally scheduled for June 22, 2026, but was adjourned for a week due to a lack of quorum. The approved proposals ", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-2feeab57b318.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:40:34", "published_display": "29 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (Nasdaq:XTLB) - Stock Analysis", "summary": "This stock analysis provides an overview of XTL Biopharmaceuticals (Nasdaq:XTLB), a biopharmaceutical company focused on autoimmune diseases. It highlights the company's financial metrics, risk factors such as high volatility and low revenue, and recent corporate developments inc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xtlb/xtl-biopharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-06-24T18:10:28", "published_display": "24 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) delays Extraordinary General Meeting after quorum shortfall", "summary": "XTL Biopharmaceuticals (XTLB) has delayed its Extraordinary General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for June 22, 2026, has been adjourned for one week and is now set to reconvene on June 29, 2026, at 4:00 p.m. Israel time, at the", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-a3ff94157fee.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:41:00", "published_display": "23 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd", "summary": "This article provides an overview of X T L Biopharmaceuticals Ltd (XTLB), focusing on its stock performance and the lack of publicly disclosed revenue breakdown data. It notes that the company's stock closed at $2.540, up 3.25%, with a market cap of $5.76 million. The detailed bu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T07:09:49", "published_display": "19 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of X T L Biopharmaceuticals Ltd (XTLB) focusing on its dividend history and stock split events. It indicates that the company has distributed no dividends over the past five years and lists two future merger-related stock splits planned for March", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T06:09:49", "published_display": "19 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Valuation: PE, PB & Fair Value Analysis", "summary": "X T L Biopharmaceuticals Ltd (XTLB) has a current valuation score of 9.97, ranking 3rd in the Biotechnology & Medical Research industry. Its P/E ratio is -3.45, with other key valuation metrics like P/B, P/S, and P/CF not yet disclosed by the company. The stock closed at $2.540, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:00", "published_display": "19 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of X T L Biopharmaceuticals Ltd (XTLB), detailing its price momentum score of 6.65, current trading range between 2.07 and 2.70, and various technical indicators. It outlines specific buy and sell signals based on MACD, RSI, KDJ, and mov", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:19", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Institutional Confidence", "summary": "The article details the institutional confidence score for X T L Biopharmaceuticals Ltd (XTLB), which currently stands at 3.00, unchanged from its previous score. It lists several key institutional shareholders and their shareholdings, noting a significant increase for Rabinovitc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:19", "published_display": "18 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for X T L Biopharmaceuticals Ltd (XTLB), noting that no specific earnings forecast score is currently available for the company. It highlights that the average score for the Biotechnology & Medical Research industry is 8.13. The report a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:19", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Financial Health: Profitability & Balance Sheet Analysis", "summary": "X T L Biopharmaceuticals Ltd (XTLB) has a weak financial status with a current financial score of 4.49, ranking 385 out of 388 in the Biotechnology & Medical Research industry. Its operating efficiency is low, and relevant financial data for quality of earnings, operational effic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T02:10:34", "published_display": "17 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) Holds Steady Near Key Support in Tight Trading Range - Scalping Stock Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUlVUWmFSbmlvUEg3a3lmcmNtV3hPWGI5dGU2U0hZd1JvXzBQS2x0V1B0ei1EWmhBaXpXbW5ZelFPUms2d1F2bVg0VnV0RDh5UWlsb2djbkJueHh1MVZwd3lEOXk0UUVadjgtUmVmdkFwejVNWDNmOTVfNEpkQ0VWektCY2U1OGlwbEotNDZuUEJKclA2TmZnNGlJMWdER0wyWU1yZkRuYWxtLVNPS2JLVm9VWktRanhj?oc=5", "source_name": "M\u011bsto B\u0159eclav", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Announces Receipt of Staff Delist Determination from Nasdaq", "summary": "XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) announced it received a delist determination from Nasdaq for failing to file its Annual Report on Form 20-F for 2025. This adds to existing non-compliance issues with minimum stockholders\u2019 equity and bid price requirements, for which the ", "url": "https://www.manilatimes.net/2026/05/23/tmt-newswire/globenewswire/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq/2350357", "source_name": "The Manila Times", "published_at": "2026-05-23T04:09:25", "published_display": "23 May 2026 04:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals faces additional Nasdaq delisting risk", "summary": "XTL Biopharmaceuticals (NASDAQ:XTLB) has received an additional Nasdaq delisting notice for failing to file its 2025 Annual Report on Form 20-F. This adds to existing non-compliance issues regarding minimum stockholders' equity and bid price. The company's stock has significantly", "url": "https://m.uk.investing.com/news/stock-market-news/xtl-biopharmaceuticals-faces-additional-nasdaq-delisting-risk-93CH-4696048?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-23T00:08:52", "published_display": "23 May 2026 00:08", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) Faces Nasdaq Compliance Challenges Amid Stock Surge", "summary": "XTL Biopharmaceuticals (XTLB) is facing Nasdaq compliance issues due to the absence of its annual report and failure to meet minimum stockholders' equity and bid price requirements. Despite these significant challenges, the stock saw a 5.98% increase in after-hours trading. The c", "url": "https://www.gurufocus.com/news/8878213/xtl-biopharmaceuticals-xtlb-faces-nasdaq-compliance-challenges-amid-stock-surge", "source_name": "GuruFocus", "published_at": "2026-05-22T21:39:52", "published_display": "22 May 2026 21:39", "sentiment": "negative", "sentiment_pct": 16, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Gets Nasdaq Noncompliance Notice", "summary": "XTL Biopharmaceuticals has received a noncompliance notice from Nasdaq because its stock's minimum bid price fell below $1 for 30 consecutive business days. The company has 180 calendar days to regain compliance by ensuring its stock trades at $1 or more for at least 10 consecuti", "url": "https://www.moomoo.com/news/post/70470351/xtl-biopharmaceuticals-gets-nasdaq-noncompliance-notice?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-22T21:08:52", "published_display": "22 May 2026 21:08", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Missed SEC filing puts XTL\u2019s Nasdaq trading status at risk", "summary": "XTL Biopharmaceuticals (Nasdaq:XTLB) has received another delist determination from Nasdaq for failing to file its 2025 Form 20-F annual report on time. This new non-compliance issue adds to existing deficiencies regarding minimum stockholders' equity and bid price, all of which ", "url": "https://www.stocktitan.net/news/XTLB/xtl-announces-receipt-of-staff-delist-determination-from-in7pwvovp42d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:52", "published_display": "22 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns XTL Biopharmaceuticals (NASDAQ: XTLB) on late 20-F and listing defects", "summary": "XTL Biopharmaceuticals (NASDAQ: XTLB) has received a delisting determination from Nasdaq due to its failure to file its Annual Report on Form 20-F for the year ended December 31, 2025. This new breach of Listing Rule 5250(c)(1) adds to existing deficiencies related to minimum sto", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-0aaf574ce571.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:52", "published_display": "22 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise", "summary": "XTL Biopharmaceuticals has called an Extraordinary General Meeting for June 22, 2026, to seek shareholder approval for the acquisition of at least 80% of Psyga Bio Ltd., a conditional private placement of up to US$1.5 million, and a significant increase in authorized share capita", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XTLB-Q/pressreleases/1979401/xtl-biopharmaceuticals-calls-june-22-2026-meeting-to-approve-psyga-bio-acquisition-and-capital-raise/", "source_name": "The Globe and Mail", "published_at": "2026-05-19T19:39:35", "published_display": "19 May 2026 19:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals schedules extraordinary shareholder meeting for June 22", "summary": "XTL Biopharmaceuticals (NASDAQ: XTLB) has announced an Extraordinary General Meeting of Shareholders to be held on June 22, 2026, at 4:00 p.m. Israel time in Tel Aviv. The company released a Notice and Proxy Statement, along with a proxy card, to outline proposals and allow share", "url": "https://www.investing.com/news/sec-filings/xtl-biopharmaceuticals-schedules-extraordinary-shareholder-meeting-for-june-22-93CH-4694104", "source_name": "Investing.com", "published_at": "2026-05-16T13:11:14", "published_display": "16 May 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTLB Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for X T L Biopharmaceuticals Ltd (XTLB), indicating a \"Sell\" consensus based on various technical indicators and moving averages. While some oscillators show \"Buy\" signals, the overall sentiment is bearish, with ", "url": "https://intellectia.ai/en/stock/XTLB/technical", "source_name": "Intellectia AI", "published_at": "2026-05-16T01:09:21", "published_display": "16 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xtl-biopharmaceuticals-acquire-psyga-bio-125800993.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T12:58:00+00:00", "published_display": "29 Apr 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | XTL Biopharmaceuticals Surges 72.6%", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOdHpGd0RtY3FhTEN5OHhrblhNMFdQRVctMll6TF9uV3RZNlVaSHJkNG1JSXU5QWRrank5SWw0VFNxNGpLaGhMckVKaXJXNmV6ZEJqWWtfM25DYVlqdWl3aGFnYU5DV0RsaWppd2FxUzNxODFkMlFkbVBfX19VbnhvTjM1MWg2b0NOUEFvTnJEeXdWMmMtU1RQcUVIdzl0ZGM?oc=5", "source_name": "Moomoo", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNR1pOU2F0YkdFd05KYWROSVcxWWtLRXlsejdKQ0QwYnZyMDg0emtadHQ1YjVGUTNqRm5vZkJrdkNpUDRVQ2tZWDA5SXBoS2h5Vk5kZ3ZjaTA1alNBYXZnenRDSFVrSnJ6RUZlQXA4WUtVeVVDTWtyYThzR2JpeGVWaTBqaWozR0U0eE5VUkNjMlBGWEJpTm45N1k3cmVSZVdmcU9PcjFfYmRTVHBDa2R4VFl3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XTL Biopharmaceuticals Limited Faces Nasdaq Delisting Following Insolvency of Subsidiary The Social Proxy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNNUc4ZXQ5WDZxMWRnYWx5Mjlnb1NRS1I5cEU0ZC1FdEJ6bFVWN1pzbG5SekxhVHI2cGEwSHZISm9jT1h5QWxqNjZQdWI5RXl1dThkWUM3RXBpYWZUMHBrREgzZ3JOSWJrMWpnZldSbGVjYnJxTzlhVEdyUnE3aEhSSHJEdUdmek5FMV9OU0EwSkR5Vi0zeHJBT3hKMld5NmRSOEI1WlZSZE9MVXo4R0xJNVhrR1VxMEN5YU91Sktjc2U4d3V6NlR5NjVmMUNQb3QweE9Naw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVXNEX3RuU0VfNWM0aDRHUW1MZ2NldHJSY21sTUVQNkZxTmZocDFKVnB3dXBpTVU2aENNWFJNZlZaQ3FPSy1kalEzcENGdTJjXzJSVDkzMlNpU2c1T1YySGc2TjByV2RJQ29WdDJBLWZxWk5obW44czRTNEpCSzk4WDBjT3ZUdzFnTW9ZalFrMlhKNUk?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals: Shifting Gears or Grounded Reality?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNWFA0UVNpTlNCakpIOWJ5LXFlUFlsemd2ck1rcTkxZjhyOHNMRV9sc1Z2LXpVRTFkV2laUTloOHRSa2N1UmI4bW1SMXFGWGtOTXI1ZUwtX0d4ZnNaUEdMZnhkaUdvMk1Pa3h3OUJ1OGJsVDRWV1FxV291OFB1ODZIYkRoT0wxUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBITDA forward of XTL Biopharmaceuticals Ltd. Sponsored ADR \u2013 LSX:A41X7J", "summary": "This article provides a financial overview, specifically the enterprise value to EBITDA forward, for XTL Biopharmaceuticals Ltd. Sponsored ADR (LSX:A41X7J) on the Lang & Schwarz Exchange. It appears to be a stub or a data point from a financial platform like TradingView, indicati", "url": "https://www.tradingview.com/symbols/LSX-A41X7J/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T05:09:50", "published_display": "12 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of XTL Biopharmaceuticals Ltd. \u2013 BOATS:XTLB", "summary": "This article identifies the enterprise value to revenue forward for XTL Biopharmaceuticals Ltd., traded under the ticker BOATS:XTLB. It appears to be a stub or a section from a financial data platform, providing a title without further details or analysis within the visible conte", "url": "https://www.tradingview.com/symbols/BOATS-XTLB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T23:10:58", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of XTL Biopharmaceuticals Ltd. \u2013 BOATS:XTLB", "summary": "This article provides the \"Price to earnings forward\" metric for XTL Biopharmaceuticals Ltd. (XTLB) listed on the Blue Ocean Alternative Trade System (BOATS) via TradingView. The page displays the current period value, change, and percentage change for this financial indicator, n", "url": "https://www.tradingview.com/symbols/BOATS-XTLB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T18:12:07", "published_display": "09 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of XTL Biopharmaceuticals Ltd. \u2013 TASE:XTLB", "summary": "This article displays the \"Enterprise value to EBIT forward\" for XTL Biopharmaceuticals Ltd. (TASE:XTLB) on TradingView. It provides financial data and indicates that the market was closed with no trades executed for the company. The page is a financial overview on TradingView fo", "url": "https://www.tradingview.com/symbols/TASE-XTLB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T11:39:25", "published_display": "08 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of XTL Biopharmaceuticals Ltd. \u2013 TASE:XTLB", "summary": "This article displays the \"Price to sales forward\" financial metric for XTL Biopharmaceuticals Ltd. (TASE:XTLB) directly from TradingView. It indicates that the company's market is currently closed with no trades recorded for this particular metric.", "url": "https://www.tradingview.com/symbols/TASE-XTLB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T04:10:09", "published_display": "08 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Completed The Acquisition Of Psyga Bio Ltd. >XTLB", "summary": "XTL Biopharmaceuticals Ltd. has completed the acquisition of Psyga Bio Ltd. This action, following the execution of a definitive transaction agreement on June 13, 2026, marks the finalization of the deal. As a result, Psyga Bio is now a wholly-owned subsidiary of XTL.", "url": "https://www.moomoo.com/news/post/72287199/xtl-completed-the-acquisition-of-psyga-bio-ltd-xtlb?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-01T20:41:45", "published_display": "01 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharma (NASDAQ: XTLB) closes Psyga Bio deal and $1.5M raise", "summary": "XTL Biopharma (NASDAQ: XTLB) has completed its acquisition of Psyga Bio Ltd., an Israeli biotechnology company focused on psychedelic and functional mushroom-derived therapeutics, making psychedelic operations its exclusive core business. XTL acquired approximately 83.40% of Psyg", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-0052a691327c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T08:09:45", "published_display": "01 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Completed the Acquisition of Psyga Bio Ltd.", "summary": "XTL Biopharmaceuticals (NASDAQ and TASE: XTLB) has completed the strategic acquisition of Psyga Bio Ltd., transforming XTL into a dedicated company in global psychedelic medicine. This acquisition expands XTL's intellectual property portfolio with clinical-stage biopharmaceutical", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/xtl-completed-the-acquisition-of-psyga-bio-ltd/2376301", "source_name": "The Manila Times", "published_at": "2026-07-01T01:10:56", "published_display": "01 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform", "summary": "XTL Biopharmaceuticals has completed the acquisition of Psyga Bio, gaining 83.40% ownership and establishing itself in the psychedelic medicine field. The acquisition provides XTL with an advanced clinical pipeline focused on Psilocybin for mental health disorders, a GMP manufact", "url": "https://www.quiverquant.com/news/XTL+Biopharmaceuticals+Completes+Acquisition+of+Psyga+Bio+to+Establish+Psychedelic+Biotechnology+Platform", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T21:20:00", "published_display": "30 Jun 2026 21:20", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL buys Psyga Bio, taking control of 83.4% of shares", "summary": "XTL Biopharmaceuticals (XTLB) has completed the acquisition of approximately 83.40% of Psyga Bio, transforming XTL into a psychedelic medicine company. This acquisition provides XTL with an advanced psilocybin-based clinical pipeline, a licensed GMP-ready manufacturing facility, ", "url": "https://www.stocktitan.net/news/XTLB/xtl-completed-the-acquisition-of-psyga-bio-17wlo192k8w4.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:09:45", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) holders pass all items at June 29 EGM", "summary": "XTL Biopharmaceuticals (XTLB) shareholders approved all proposals at their Extraordinary General Meeting (EGM) held on June 29, 2026, in Tel Aviv. The meeting was originally scheduled for June 22, 2026, but was adjourned for a week due to a lack of quorum. The approved proposals ", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-2feeab57b318.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:40:34", "published_display": "29 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (Nasdaq:XTLB) - Stock Analysis", "summary": "This stock analysis provides an overview of XTL Biopharmaceuticals (Nasdaq:XTLB), a biopharmaceutical company focused on autoimmune diseases. It highlights the company's financial metrics, risk factors such as high volatility and low revenue, and recent corporate developments inc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xtlb/xtl-biopharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-06-24T18:10:28", "published_display": "24 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) delays Extraordinary General Meeting after quorum shortfall", "summary": "XTL Biopharmaceuticals (XTLB) has delayed its Extraordinary General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for June 22, 2026, has been adjourned for one week and is now set to reconvene on June 29, 2026, at 4:00 p.m. Israel time, at the", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-a3ff94157fee.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:41:00", "published_display": "23 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd", "summary": "This article provides an overview of X T L Biopharmaceuticals Ltd (XTLB), focusing on its stock performance and the lack of publicly disclosed revenue breakdown data. It notes that the company's stock closed at $2.540, up 3.25%, with a market cap of $5.76 million. The detailed bu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T07:09:49", "published_display": "19 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of X T L Biopharmaceuticals Ltd (XTLB) focusing on its dividend history and stock split events. It indicates that the company has distributed no dividends over the past five years and lists two future merger-related stock splits planned for March", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T06:09:49", "published_display": "19 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Valuation: PE, PB & Fair Value Analysis", "summary": "X T L Biopharmaceuticals Ltd (XTLB) has a current valuation score of 9.97, ranking 3rd in the Biotechnology & Medical Research industry. Its P/E ratio is -3.45, with other key valuation metrics like P/B, P/S, and P/CF not yet disclosed by the company. The stock closed at $2.540, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:00", "published_display": "19 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of X T L Biopharmaceuticals Ltd (XTLB), detailing its price momentum score of 6.65, current trading range between 2.07 and 2.70, and various technical indicators. It outlines specific buy and sell signals based on MACD, RSI, KDJ, and mov", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:19", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Institutional Confidence", "summary": "The article details the institutional confidence score for X T L Biopharmaceuticals Ltd (XTLB), which currently stands at 3.00, unchanged from its previous score. It lists several key institutional shareholders and their shareholdings, noting a significant increase for Rabinovitc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:19", "published_display": "18 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for X T L Biopharmaceuticals Ltd (XTLB), noting that no specific earnings forecast score is currently available for the company. It highlights that the average score for the Biotechnology & Medical Research industry is 8.13. The report a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:19", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X T L Biopharmaceuticals Ltd (XTLB) Financial Health: Profitability & Balance Sheet Analysis", "summary": "X T L Biopharmaceuticals Ltd (XTLB) has a weak financial status with a current financial score of 4.49, ranking 385 out of 388 in the Biotechnology & Medical Research industry. Its operating efficiency is low, and relevant financial data for quality of earnings, operational effic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xtlb/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T02:10:34", "published_display": "17 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) Holds Steady Near Key Support in Tight Trading Range - Scalping Stock Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUlVUWmFSbmlvUEg3a3lmcmNtV3hPWGI5dGU2U0hZd1JvXzBQS2x0V1B0ei1EWmhBaXpXbW5ZelFPUms2d1F2bVg0VnV0RDh5UWlsb2djbkJueHh1MVZwd3lEOXk0UUVadjgtUmVmdkFwejVNWDNmOTVfNEpkQ0VWektCY2U1OGlwbEotNDZuUEJKclA2TmZnNGlJMWdER0wyWU1yZkRuYWxtLVNPS2JLVm9VWktRanhj?oc=5", "source_name": "M\u011bsto B\u0159eclav", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Announces Receipt of Staff Delist Determination from Nasdaq", "summary": "XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) announced it received a delist determination from Nasdaq for failing to file its Annual Report on Form 20-F for 2025. This adds to existing non-compliance issues with minimum stockholders\u2019 equity and bid price requirements, for which the ", "url": "https://www.manilatimes.net/2026/05/23/tmt-newswire/globenewswire/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq/2350357", "source_name": "The Manila Times", "published_at": "2026-05-23T04:09:25", "published_display": "23 May 2026 04:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals faces additional Nasdaq delisting risk", "summary": "XTL Biopharmaceuticals (NASDAQ:XTLB) has received an additional Nasdaq delisting notice for failing to file its 2025 Annual Report on Form 20-F. This adds to existing non-compliance issues regarding minimum stockholders' equity and bid price. The company's stock has significantly", "url": "https://m.uk.investing.com/news/stock-market-news/xtl-biopharmaceuticals-faces-additional-nasdaq-delisting-risk-93CH-4696048?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-23T00:08:52", "published_display": "23 May 2026 00:08", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals (XTLB) Faces Nasdaq Compliance Challenges Amid Stock Surge", "summary": "XTL Biopharmaceuticals (XTLB) is facing Nasdaq compliance issues due to the absence of its annual report and failure to meet minimum stockholders' equity and bid price requirements. Despite these significant challenges, the stock saw a 5.98% increase in after-hours trading. The c", "url": "https://www.gurufocus.com/news/8878213/xtl-biopharmaceuticals-xtlb-faces-nasdaq-compliance-challenges-amid-stock-surge", "source_name": "GuruFocus", "published_at": "2026-05-22T21:39:52", "published_display": "22 May 2026 21:39", "sentiment": "negative", "sentiment_pct": 16, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Gets Nasdaq Noncompliance Notice", "summary": "XTL Biopharmaceuticals has received a noncompliance notice from Nasdaq because its stock's minimum bid price fell below $1 for 30 consecutive business days. The company has 180 calendar days to regain compliance by ensuring its stock trades at $1 or more for at least 10 consecuti", "url": "https://www.moomoo.com/news/post/70470351/xtl-biopharmaceuticals-gets-nasdaq-noncompliance-notice?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-22T21:08:52", "published_display": "22 May 2026 21:08", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Missed SEC filing puts XTL\u2019s Nasdaq trading status at risk", "summary": "XTL Biopharmaceuticals (Nasdaq:XTLB) has received another delist determination from Nasdaq for failing to file its 2025 Form 20-F annual report on time. This new non-compliance issue adds to existing deficiencies regarding minimum stockholders' equity and bid price, all of which ", "url": "https://www.stocktitan.net/news/XTLB/xtl-announces-receipt-of-staff-delist-determination-from-in7pwvovp42d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:52", "published_display": "22 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns XTL Biopharmaceuticals (NASDAQ: XTLB) on late 20-F and listing defects", "summary": "XTL Biopharmaceuticals (NASDAQ: XTLB) has received a delisting determination from Nasdaq due to its failure to file its Annual Report on Form 20-F for the year ended December 31, 2025. This new breach of Listing Rule 5250(c)(1) adds to existing deficiencies related to minimum sto", "url": "https://www.stocktitan.net/sec-filings/XTLB/6-k-xtl-biopharmaceuticals-ltd-current-report-foreign-issuer-0aaf574ce571.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:52", "published_display": "22 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise", "summary": "XTL Biopharmaceuticals has called an Extraordinary General Meeting for June 22, 2026, to seek shareholder approval for the acquisition of at least 80% of Psyga Bio Ltd., a conditional private placement of up to US$1.5 million, and a significant increase in authorized share capita", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XTLB-Q/pressreleases/1979401/xtl-biopharmaceuticals-calls-june-22-2026-meeting-to-approve-psyga-bio-acquisition-and-capital-raise/", "source_name": "The Globe and Mail", "published_at": "2026-05-19T19:39:35", "published_display": "19 May 2026 19:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals schedules extraordinary shareholder meeting for June 22", "summary": "XTL Biopharmaceuticals (NASDAQ: XTLB) has announced an Extraordinary General Meeting of Shareholders to be held on June 22, 2026, at 4:00 p.m. Israel time in Tel Aviv. The company released a Notice and Proxy Statement, along with a proxy card, to outline proposals and allow share", "url": "https://www.investing.com/news/sec-filings/xtl-biopharmaceuticals-schedules-extraordinary-shareholder-meeting-for-june-22-93CH-4694104", "source_name": "Investing.com", "published_at": "2026-05-16T13:11:14", "published_display": "16 May 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTLB Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for X T L Biopharmaceuticals Ltd (XTLB), indicating a \"Sell\" consensus based on various technical indicators and moving averages. While some oscillators show \"Buy\" signals, the overall sentiment is bearish, with ", "url": "https://intellectia.ai/en/stock/XTLB/technical", "source_name": "Intellectia AI", "published_at": "2026-05-16T01:09:21", "published_display": "16 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xtl-biopharmaceuticals-acquire-psyga-bio-125800993.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T12:58:00+00:00", "published_display": "29 Apr 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | XTL Biopharmaceuticals Surges 72.6%", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOdHpGd0RtY3FhTEN5OHhrblhNMFdQRVctMll6TF9uV3RZNlVaSHJkNG1JSXU5QWRrank5SWw0VFNxNGpLaGhMckVKaXJXNmV6ZEJqWWtfM25DYVlqdWl3aGFnYU5DV0RsaWppd2FxUzNxODFkMlFkbVBfX19VbnhvTjM1MWg2b0NOUEFvTnJEeXdWMmMtU1RQcUVIdzl0ZGM?oc=5", "source_name": "Moomoo", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNR1pOU2F0YkdFd05KYWROSVcxWWtLRXlsejdKQ0QwYnZyMDg0emtadHQ1YjVGUTNqRm5vZkJrdkNpUDRVQ2tZWDA5SXBoS2h5Vk5kZ3ZjaTA1alNBYXZnenRDSFVrSnJ6RUZlQXA4WUtVeVVDTWtyYThzR2JpeGVWaTBqaWozR0U0eE5VUkNjMlBGWEJpTm45N1k3cmVSZVdmcU9PcjFfYmRTVHBDa2R4VFl3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Limited Faces Nasdaq Delisting Following Insolvency of Subsidiary The Social Proxy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNNUc4ZXQ5WDZxMWRnYWx5Mjlnb1NRS1I5cEU0ZC1FdEJ6bFVWN1pzbG5SekxhVHI2cGEwSHZISm9jT1h5QWxqNjZQdWI5RXl1dThkWUM3RXBpYWZUMHBrREgzZ3JOSWJrMWpnZldSbGVjYnJxTzlhVEdyUnE3aEhSSHJEdUdmek5FMV9OU0EwSkR5Vi0zeHJBT3hKMld5NmRSOEI1WlZSZE9MVXo4R0xJNVhrR1VxMEN5YU91Sktjc2U4d3V6NlR5NjVmMUNQb3QweE9Naw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVXNEX3RuU0VfNWM0aDRHUW1MZ2NldHJSY21sTUVQNkZxTmZocDFKVnB3dXBpTVU2aENNWFJNZlZaQ3FPSy1kalEzcENGdTJjXzJSVDkzMlNpU2c1T1YySGc2TjByV2RJQ29WdDJBLWZxWk5obW44czRTNEpCSzk4WDBjT3ZUdzFnTW9ZalFrMlhKNUk?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XTL Biopharmaceuticals: Shifting Gears or Grounded Reality?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNWFA0UVNpTlNCakpIOWJ5LXFlUFlsemd2ck1rcTkxZjhyOHNMRV9sc1Z2LXpVRTFkV2laUTloOHRSa2N1UmI4bW1SMXFGWGtOTXI1ZUwtX0d4ZnNaUEdMZnhkaUdvMk1Pa3h3OUJ1OGJsVDRWV1FxV291OFB1ODZIYkRoT0wxUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 85, "total_relevant": 44, "sentiment_summary": {"positive": 6, "negative": 11, "neutral": 27, "score": 46, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 2.91, "latest_week": "2026-07-10", "one_week_move": 7.8, "four_week_move": 36.6, "twelve_week_move": 18.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.77461, "market_dynamics_buy_signal": true, "relative_strength": -33.467886, "fair_value_gap": -47.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.1687, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.8% over one week, +36.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Market Dynamics buy signal", "Value support"], "opportunities": ["Market Dynamics is showing a buy signal in the latest weekly context.", "Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 7}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "Moomoo", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "The Manila Times", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 8}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.8% over one week, +36.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBITDA forward of XTL Biopharmaceuticals Ltd. Sponsored ADR \u2013 LSX:A41X7J"}], "updated_at": "2026-07-16T05:41:37.851079+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}